|
|
|
201-500 employees
View all
|
|
biotechnology
|
|
Rockville, Maryland (MD), United States
|
|
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
Revenue: 10.4 MILLION USD
|
REGENXBIO Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
100%
|
The widely used REGENXBIO Inc. email format is {f}{last} (e.g. [email protected]) with 100% adoption across the company.
To contact REGENXBIO Inc. customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.